About
Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment
Our Mission
To advance a new generation of genetic medicines through genome engineering. Leveraging decades of expertise in programmable DNA-binding proteins, we develop innovative therapeutic approaches designed to edit, rewrite, and reprogram biological function.
Governance
Cellectis is committed to good corporate governance, which promotes the long-term interests of shareholders, strengthens the Board of Directors and management accountability and helps build public trust in the Company. Our business practices foster our strong innovative and collaborative culture, which is committed to ethical behavior, accountability and transparency.
Partners
Cellectis has established collaborations with leading biotechnology and pharmaceutical companies, including AstraZeneca, Servier, Allogene and Iovance, leveraging its genome engineering expertise across cell therapy and genetic medicine applications.
Corporate social responsibility
Cellectis is committed to advancing genetic medicines responsibly and sustainably. By leveraging our genome engineering expertise, we seek to develop innovative therapies for serious diseases while maintaining the highest standards of ethics, scientific rigor and corporate responsibility. Through our employees, technologies and partnerships, we aim to contribute positively to patients, society and the communities in which we operate.
Cellectis’ Ethics Charter
By signing the Group’s Ethics Charter, each member of Cellectis commits to upholding its standards. For example, the values defended in this Charter cover the employee work conditions, as well as research objectives. Cellectis expects its associates, as well as its providers and subcontractors, to comply with this Charter in execution of their activities on a daily basis. They are also expected to respect human rights, labor rights, and the environment.
Media contacts
For more information on any story, or for press enquiries, get in touch with our communication team